Top

Published in:

01-08-2016 | Original Paper

Quality of psoriasis care in Germany: results of the national health care study “PsoHealth3”

Authors: Anna Langenbruch, Marc Alexander Radtke, Arnd Jacobi, Sandra Purwins, Kristina Haack, Kristian Reich, Klaus Stroemer, Ulrich Mrowietz, Matthias Augustin

Published in: Archives of Dermatological Research | Issue 6/2016

Abstract

Two national surveys conducted in 2005 and 2007 indicated deficits in psoriasis care and induced the composition of the ‘‘National Goals for Health Care in Psoriasis 2010–2015’’. The aim of this work was to (1) evaluate the quality of care for patients with psoriasis in Germany, (2) compare this with prior psoriasis studies PsoHealth1 (2005) and PsoHealth2 (2007), and (3) review the implementation of national treatment goals. By means of a cross sectional study the following indicators of health care quality were collected: psoriasis severity (Psoriasis Area Severity Index (PASI) and proportion of PASI >20), quality of life (Dermatology Life Quality Index (DLQI) were corporated: proportion of DLQI >10), previous systemic treatment, inpatient treatment, and days absent from work due to psoriasis. Between January 2013 and March 2014, 1265 patients from 82 dermatological centres were included (mean age of 52 years). 9.2 % had a PASI >20 (2007: 11.6 %; 2005: 17.8 %). 21.3 % reported strong quality of life restrictions (DLQI >10) (2007: 28.2 %; 2005: 34.0 %). 59.5 % had received a systemic treatment at least once within the last 5 years (2007: 47.3 %; 2005: 32.9 %). 20.1 % were treated inpatient within the last 5 years (2007: 20.1 %; 2005: 26.9 %). The current data indicate a better health care situation for psoriasis in Germany. The implementation of the S3-Guideline and the ‘‘National Goals for Health Care in Psoriasis 2010–2015’’ could have been contributing factors.

Augustin M (2008) PsoNet—more health care quality through regional psoriasis networks. J Dtsch Dermatol Ges 6(4):263–264CrossRefPubMed

Augustin M, Alvaro-Gracia JM, Bagot M et al (2012) A framework for improving the quality of care for people with psoriasis. J Eur Acad Dermatol Venereol 26(Suppl 4):1–16CrossRefPubMed

Augustin M, Chapnik J, Gupta S et al (2011) Psoriasis causes high costs, reduces productivity at work and quality of life. Akt Dermatol 37(10):353–359CrossRef

Augustin M, Glaeske G, Radtke MA et al (2010) Epidemiology and comorbidity of psoriasis in children. Br J Dermatol 162(3):633–636CrossRefPubMed

Augustin M, Glaeske G, Schäfer I et al (2012) Processes of Psoriasis Health Care in Germany—long-term analysis of data from the statutory health insurances. J Dtsch Dermatol Ges 10(9):648–655PubMed

Augustin M, Herberger K, Hintzen S et al (2011) Prevalence of skin lesions and need for treatment in a cohort of 90,880 workers. Br J Dermatol 165(4):865–873CrossRefPubMed

Augustin M, Krüger K, Radtke MA et al (2008) Disease severity, quality of life and health care in plaque-type psoriasis: a multicenter cross-sectional study in Germany. Dermatology 216(4):366–372CrossRefPubMed

Augustin M, Radtke MA, Zschocke I et al (2009) The patient benefit index: a novel approach in patient-defined outcomes measurement for skin diseases. Arch Dermatol Res 301(8):561–571CrossRefPubMed

Augustin M, Reich K, Blome C et al (2010) Nail psoriasis in Germany: epidemiology and burden of disease. Br J Dermatol 163(3):580–585CrossRefPubMed

10.

Augustin M, Reich K, Glaeske G et al (2013) Drug supply for children with psoriasis in Germany. J Dtsch Dermatol Ges 11(8):751–755PubMed

11.

Augustin M, Reich K, Reich C et al (2008) Quality of psoriasis care in Germany—results of the national study PsoHealth 2007. J Dtsch Dermatol Ges 6(8):640–645CrossRefPubMed

12.

Augustin M, Schäfer I, Reich K et al (2011) Systemic treatment with corticosteroids in psoriasis-health care provision far beyond the S3-guidelines. J Dtsch Dermatol Ges 9(10):833–838PubMed

13.

Augustin M, Zschocke I, Seidenglanz K et al (2000) Validation and clinical results of the FLQA-d, a quality of life questionnaire for patients with chronic skin diseases. Dermatol Psychosom 1(1):12–17CrossRef

14.

Blome C, Simianer S, Purwins S et al (2010) Time needed for treatment is the major predictor of quality of life in psoriasis. Dermatology 221(2):154–159CrossRefPubMed

15.

Deutsche Dermatologische Gesellschaft (DDG), Berufsverband der Deutschen Dermatologen (BVDD) (2015) Regionale Psoriasisnetze in Deutschland. http://www.psonet.de. Accessed 6 Jan 2015

16.

Deutsche Dermatologische Gesellschaft (DDG), Berufsverband der Deutschen Dermatologen (BVDD), Competenzzentrum Versorgungsforschung in der Dermatologie (CVderm) (2014) Psoriasis Nationale Versorgungsziele. http://www.versorgungsziele.de/. Accessed 19 Dec 2014

17.

Dubertret L, Mrowietz U, Ranki A et al (2006) European patient perspectives on the impact of psoriasis: the EUROPSO patient membership survey. Br J Dermatol 155(4):729–736CrossRefPubMed

18.

Feldman SR, Krueger GG (2005) Psoriasis assessment tools in clinical trials. Ann Rheum Dis 64(Suppl 2):ii65–ii68PubMedPubMedCentral

19.

Feuerhahn J, Blome C, Radtke M et al (2012) Validation of the patient benefit index for the assessment of patient-relevant benefit in the treatment of psoriasis. Arch Dermatol Res 304(6):433–441CrossRefPubMed

20.

Finlay AY, Khan GK (1994) Dermatology Life Quality Index (DLQI)—a simple practical measure for routine clinical use. Clin Exp Dermatol 19(3):210–216CrossRefPubMed

21.

Kimball AB, Gieler U, Linder D et al (2010) Psoriasis: is the impairment to a patient’s life cumulative? J Eur Acad Dermatol Venereol 24(9):989–1004PubMed

22.

Krueger G, Koo J, Lebwohl M et al (2001) The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol 137(3):280–284PubMed

23.

Nast A, Kopp IB, Augustin M et al (2006) S3-guidelines for the treatment of psoriasis vulgaris. J Dtsch Dermatol Ges 4(Suppl2):S1–126CrossRefPubMed

24.

Radtke MA, Reich K, Blome C et al (2009) Evaluation of quality of care and guideline-compliant treatment in psoriasis. Development of a new system of quality indicators. Dermatology 219(1):54–58CrossRefPubMed

25.

Radtke MA, Reich K, Blome C et al (2009) Prevalence and clinical features of psoriatic arthritis and joint complaints in 2009 patients with psoriasis: results of a German national survey. J Eur Acad Dermatol Venereol 23(6):683–691CrossRefPubMed

26.

Reich K, Krüger K, Mössner R et al (2009) Epidemiology and clinical pattern of psoriatic arthritis in Germany: a prospective interdisciplinary epidemiological study of 1511 patients with plaque-type psoriasis. Br J Dermatol 160(5):1040–1047CrossRefPubMed

27.

Schmid-Ott G, Künsebeck H, Jäger B et al (2005) Significance of the stigmatization experience of psoriasis patients: a 1-year follow-up of the illness and its psychosocial consequences in men and women. Acta Derm Venereol 85(1):27–32CrossRefPubMed

28.

Schöffski O, Augustin M, Prinz J et al (2007) Costs and quality of life in patients with moderate-to-severe plaque-type psoriasis in Germany: a multi-center study. J Dtsch Dermatol Ges 5(3):209–218CrossRefPubMed

29.

Sohn S, Schoeffski O, Prinz J et al (2006) Cost of moderate to severe plaque psoriasis in Germany: a multicenter cost-of-illness study. Dermatology 212(2):137–144CrossRefPubMed

30.

Taylor WJ (2012) Impact of psoriatic arthritis on the patient: through the lens of the WHO International Classification of Functioning, Health, and Disability. Curr Rheumatol Rep 14(4):369–374CrossRefPubMed

31.

Zachariae H, Zachariae R, Blomqvist K et al (2002) Quality of life and prevalence of arthritis reported by 5,795 Members of the Nordic Psoriasis Associations. Data from the Nordic Quality of Life Study. Acta Derm Venereol 82(2):108–113CrossRefPubMed

Title: Quality of psoriasis care in Germany: results of the national health care study “PsoHealth3”
Authors: Anna Langenbruch
Marc Alexander Radtke
Arnd Jacobi
Sandra Purwins
Kristina Haack
Kristian Reich
Klaus Stroemer
Ulrich Mrowietz
Matthias Augustin
Publication date: 01-08-2016
Publisher: Springer Berlin Heidelberg
Published in: Archives of Dermatological Research / Issue 6/2016
Print ISSN: 0340-3696
Electronic ISSN: 1432-069X
DOI: https://doi.org/10.1007/s00403-016-1651-x

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Quality of psoriasis care in Germany: results of the national health care study “PsoHealth3”

Abstract

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2016

The German National Program on Psoriasis Health Care 2005–2015: results and experiences

ULBP3: a marker for alopecia areata incognita

TOX expression in cutaneous B-cell lymphomas

Immunohistochemical study of toll-like receptors 2, 4, and 9 expressions in pemphigus and bullous pemphigoid lesions

Olfactory functions in patients with psoriasis vulgaris: correlations with the severity of the disease

Reply to the letter to the editor on: “In psoriasis, levels of hope and quality of life are linked”